Navigation Links
Diaceutics and London Genetics Partner to Accelerate Biomarker Development in the Global Biopharmaceutical Industry
Date:9/15/2010

pecializing in personalized medicine. Diaceutics mission is to build bridges between pharmaceutical and diagnostic companies and to provide pharmaceutical industry leaders with the foundation and operational structure necessary to effectively develop and commercialize targeted therapies that better meet patients' needs and improve return on investment. For more information, visit http://www.diaceutics.com.

About Pharmacogenetics:

Genetic differences between individuals mean that drug response rates are often variable across a population, and this has significant implications for healthcare cost effectiveness. Pharmocogenetics, the study of the clinical consequences of genetic differences in the way people metabolise and respond to drugs, is expected to generate better understanding of how drugs work in the body, and therefore give insight into how to develop more efficacious and safer drugs. It also has implications for product life cycle management and the revitalisation of drugs which previously failed in clinical trials. With drug development costs rising and R&D productivity falling, plus increased regulator focus on safety and cost-effectiveness, pharmacogenetics is expected to become increasingly important in drug development. The FDA and the EMA have recognised this in their Critical Path Initiative and Road Map respectively.

Contact for London Genetics Ltd: Dominique Kleyn, CEO, +44-(0)207-594-1838 Emma Palmer Foster, Strategic Communications Consultant, +44-(0)7880-787-185 communications@londongenetics.com Contact for Diaceutics: Mollie Roth, Esq., Chief Operating Officer +1-202-280-5887 mollie.roth@diaceutics.com
'/>"/>

SOURCE London Genetics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. OXIS International, Inc. Announces Its Attendance at the Rodman & Renshaw Annual Global Investment Conference in London, May 16-18, 2010
2. London Genetics Conference Proceedings Published in Drug Discovery Today
3. First Awards Made by London Genetics Proof-of-Concept Fund
4. Expanded London Genetics Web Site Emphasises Importance of Pharmacogenetics in Drug Development
5. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
6. London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference
7. PRA International: Participating Sponsor for Exploratory Clinical Development World in London
8. Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome
9. Reportlinker Adds Epigenetics: Current and future applications that are driving novel drug discovery
10. Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress® to Its Sequencing and Genotyping Capabilities
11. Interleukin Genetics Moves Trading of Stock to OTCQB Marketplace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. ... amended and increased its five-year revolving credit facility to ... an accordion feature that will allow the company to ... additional $30.0 million, subject to securing additional commitments from ... of the credit facility remains December 18, 2018.   ...
(Date:4/23/2015)... CHICAGO, Ill. , April 24, 2015  AbbVie ... Food and Drug Administration (FDA) has accepted its New ... company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, ... for the treatment of adults with chronic genotype 4 ... regimen is the first all-oral, interferon-free therapy being evaluated ...
(Date:4/23/2015)... Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that ... on Thursday, May 7, 2015, after the close of ... audio webcast immediately following the announcement at 4:30 p.m. ... results and provide a business and financial update. ... via the Investors & Media section of the Jazz ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 2
... NOVATO, Calif., Sept. 30 BioMarin Pharmaceutical Inc. (Nasdaq: ... and Trademark Office has allowed claims covering the approved ... the discovery that food increases the bioavailability of Kuvan. ... in 2024, will officially issue later this year. , ...
... Delaware-based company specializing in pharmaceutical risk management and optimal ... chief marketing executive in a move to expand the ... served as interim vice president of business development, sales ... consultant to Acurian and NanoScan Imaging. She is ...
Cached Medicine Technology:United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 2United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 3
(Date:4/26/2015)... From March 18th, 2015 toward the ... Master™ Dahryn Trivedi, spent a month traveling in India ... institutions in the efforts of creating highly advanced, effective ... for human health care. , During their journey, ... institutions. All lab facilities are approved by the U.S. ...
(Date:4/26/2015)... April 26, 2015 This annual celebration ... the season and will include a spectacular collection of ... collectibles, herbal soaps and incense, chimes, vases, candleholders, fleece ... year’s exciting and unique collection of vendors, guests will ... Jim Martocci and the Jimmie Jazz Band. , ...
(Date:4/26/2015)... Hartford, CT (PRWEB) April 26, 2015 The ... welcome and reflection by Deb Dettor, CCAR’s Managing Director. Deb ... Phil Valentine who was not in attendance because of his ... To everyone’s delight, Phil was able to express his gratitude ... thanked the volunteers for their dedication to carrying out CCAR’s ...
(Date:4/25/2015)... ME (PRWEB) April 26, 2015 ... Canadian based integrative healthcare event. The Integrative Healthcare ... place October 23-24, 2015 at the Sheraton Parkway ... Symposium Canada is one of the most anticipated ... clinically relevant, evidenced-based CME program. The event aims ...
(Date:4/25/2015)... 2015 The Hon. Ellen Tauscher, Independent ... the following statement following the deadly earthquake in Nepal: ... resulting in the deaths of more than 1,000 people. ... across Nepal, Bangladesh, India and other parts of South ... to the people of Nepal and the families of ...
Breaking Medicine News(10 mins):Health News:Trivedi Science™ Has Started Scientific Research to Create More Effective Pharmaceuticals and Nutraceuticals 2Health News:Trivedi Science™ Has Started Scientific Research to Create More Effective Pharmaceuticals and Nutraceuticals 3Health News:It’s Coming! The 5th Annual Tulip Festival & Mother’s Day Celebration at Honor's Haven Resort & Spa! 2Health News:The Connecticut Community for Addiction Recovery (CCAR) honors its volunteers during National Volunteer Recognition Week. 2Health News:Integrative Healthcare Event launching in Canada 2
... participate in school-sponsored and club-level gymnastics competitions annually in ... in terms of potential for injury, while having one ... , A study, conducted by researchers in the Center ... Institute at Nationwide Childrens Hospital and published in the ...
... 4, 2008 Dialysis,Corporation of America (Nasdaq: DCAI ... its eleventh facility in that state., President & ... our growth in Pennsylvania, one of our core markets ... superior quality,care for the patients we are responsible for ...
... April 4, 2008 Companies align,commercial and portfolio ... an annual sales volume of $10 to 20 ... the early-stage commercialization team along,with approximately eight portfolio ... is approximately four to three, commercial to,portfolio management ...
... INDIANAPOLIS, April 4, 2008 Eli Lilly and ... European Commission has approved a new,indication for FORSTEO(R) ... associated with sustained, systemic,glucocorticoid therapy in women and ... the initial positive opinion issued in February by,the ...
... 2008 To promote,the U.S. Department of ... a,Healthy Future" initiative, Acting U.S. Surgeon General ... with several community leaders at A.I.,DuPont Hospital ... reducing,childhood obesity in Delaware., (Photo: httphttp://www.newscom.com/cgi-bin/prnh/20080403/18521), ...
... 2008 Targeted mass,media campaigns alone can ... young adults to adopt safer,sex practices, according ... of,Communication at the University of Kentucky with ... Past public health campaigns, particularly those ...
Cached Medicine News:Health News:Dialysis Corporation of America Announces the Development of a New Facility in Pennsylvania 2Health News:Early-stage Commercialization Success: Pharma Companies Adjust Resources in Light of Industry Changes 2Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 2Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 3Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 4Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 5Health News:Delaware's Campaign to Make Kids Healthy Gets Boost from US Top Doc 2Health News:Delaware's Campaign to Make Kids Healthy Gets Boost from US Top Doc 3Health News:Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults 2Health News:Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults 3
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
... international engineering and design specifications, Smith ... System* provides seamless integration with existing ... open reduction internal fixational procedures (AO ... well beyond the standard, providing a ...
... has been developed for the transvenous closure ... venous sheaths the device offers a safe ... of ASD's with a super low profile.,A ... twelve arm device for optimal positioning and ...
Stainless steel threaded Steinman Pins available in point types A,D, E, and F....
Medicine Products: